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Abstract
Cervical cancer cells commonly harbour a defective G1/S checkpoint owing to the interac-
tion of viral oncoproteins with p53 and retinoblastoma protein. The activation of the G2/M
checkpoint may thus become essential for protecting cancer cells from genotoxic insults,
such as chemotherapy. In 52 cervical cancer patients treated with neoadjuvant chemother-
apy, we investigated whether the levels of phosphorylated Wee1 (pWee1), a key G2/M
checkpoint kinase, and γ-H2AX, a marker of DNA double-strand breaks, discriminated
between patients with a pathological complete response (pCR) and those with residual dis-
ease. We also tested the association between pWee1 and phosphorylated Chk1 (pChk1), a
kinase acting upstreamWee1 in the G2/M checkpoint pathway. pWee1, γ-H2AX and pChk1
were retrospectively assessed in diagnostic biopsies by immunohistochemistry. The
degrees of pWee1 and pChk1 expression were defined using three different classification
methods, i.e., staining intensity, Allred score, and a multiplicative score. γ-H2AX was ana-
lyzed both as continuous and categorical variable. Irrespective of the classification used,
elevated levels of pWee1 and γ-H2AX were significantly associated with a lower rate of
pCR. In univariate and multivariate analyses, pWee1 and γ-H2AX were both associated
with reduced pCR. Internal validation conducted through a re-sampling without replacement
procedure confirmed the robustness of the multivariate model. Finally, we found a
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significant association between pWee1 and pChk1. The message conveyed by the present
analysis is that biomarkers of DNA damage and repair may predict the efficacy of neoadju-
vant chemotherapy in cervical cancer. Further studies are warranted to prospectively vali-
date these encouraging findings.
Introduction
Eukaryotic cells are constantly exposed to endogenous and exogenous sources of DNA damage.
The transmission of undamaged DNA to the offspring is ensured by a complex molecular net-
work, the DNA damage response (DDR), which operates through the coordinated activity of
cell cycle checkpoints, DNA repair mechanisms and apoptotic pathways [1, 2]. The presence of
genetic lesions triggers checkpoint-mediated arrest of the cell cycle [2]. This event enables
DNA repair effectors and apoptotic pathways to repair the lesion or eliminate irremediably
damaged cells, respectively.
Cancer cells aberrantly use DNA repair mechanisms to survive stressful conditions, such as
exposure to chemotherapy [2]. A common trait to a variety of tumors is the defective nature of
the G1/S-phase checkpoint, stemming from mutational or functional inactivation of p53 or ret-
inoblastoma protein (pRb) [3]. When this occurs, cancer cells become extremely dependent on
the G2/M checkpoint for cell cycle arrest and DNA repair [3]. The ataxia telangiectasia and
Rad3-related protein (ATR)-Checkpoint kinase 1 (Chk1)-Wee1-like protein kinase (Wee1)
cascade represents the core of the G2/M checkpoint, whose activation leads to the inhibition of
the cyclin-dependent kinase 1 and culminates into checkpoint-mediated cell cycle arrest [3]. In
such a manner, cancer cells have the time to correct chemotherapy-induced DNA lesions,
avoiding entry into a lethal mitosis known as mitotic catastrophe [4]. G2/M checkpoint depen-
dency in a p53-defective molecular background is a concept currently exploited for the clinical
development of synthetic lethality-based therapeutics. When G1/S-phase checkpoint-defective
cells are exposed to chemotherapeutics, the concomitant pharmacological inhibition of G2/M
checkpoint kinases is deleterious for cell fitness [3].
We reasoned that G2/M checkpoint “addiction” for compensating p53 or pRb defects upon
exposure to genotoxic agents can be exploited in the search for predictive biomarkers foreseeing
chemotherapy sensitivity/resistance. In this exploratory analysis we focused on cervical cancer,
the prototype of p53- and pRb-defective tumors. Indeed, human papillomavirus E6 and E7 onco-
proteins promote ubiquitin-mediated degradation of p53 and pRb, respectively [5]. We thus ret-
rospectively investigated the association between the levels of DNA damage and repair
biomarkers, assessed in bioptic samples collected from untreated patients at the time of diagnosis,
and pathological complete response (pCR) after neoadjuvant chemotherapy, i.e., chemotherapy
delivered in the timeframe between diagnostic biopsy and the surgical resection. All the patients
were homogenously treated with paclitaxel, ifosfamide and cisplatin (TIP regimen). We focused
on phosphorylatedWee1 (pWee1) as a proxy of G2/M checkpoint activation, and phosphory-
lated H2A Histone Family Member X (γ-H2AX) as a marker of DNA double-strand breaks.
Phosphorylated Chk1 (pChk1) was tested in a fraction of samples for a signaling study.
Materials and Methods
Study Participants and Procedures
Fifty-two histologically confirmed cervical cancer patients (stage Ib2-IIIa) who received neoad-
juvant chemotherapy were included in this retrospective analysis. All patients were treated
DNA Damage Repair in Cervical Cancer Patients
PLOS ONE | DOI:10.1371/journal.pone.0149872 March 1, 2016 2 / 11
hosphorylated Chk1; γ-H2AX, phosphorylated H2A
Histone Family Member X; pRb, retinoblastoma
protein; pWee1, phosphorylated Wee1; Wee1, Wee1-
like protein kinase.
with the TIP regimen (paclitaxel 175 mg/m2 on day 1 + ifosfamide 2500 mg/m2 on days 1 and
2 + cisplatin 50 mg/m2 on day 2 every 21 days for three or four cycles) followed by radical sur-
gery. Patients were considered eligible if they completed the planned treatment, data on clinical
features and treatment outcomes were available, and the amount of biological materials in their
biopsies was sufficient for molecular analyses. pCR was defined as no residual disease in surgi-
cal samples. The immunohistochemical assessment of pWee1, γ-H2AX, and pChk1 was per-
formed in formalin-fixed paraffin-embedded (FFPE) tissues, obtained from the biological
specimens collected through bioptic procedures in untreated patients, using the following anti-
bodies: anti-phospho-H2AX (Ser139) (clone JBW301) mouse monoclonal antibody (MAb)
(Upstate, NY, USA) at the dilution of 1:500, anti-phospho-Wee1 (Ser642) (clone D47G5) rab-
bit MAb (Cell Signaling, Danvers, MA, USA) at the dilution of 1:100, and anti-phospho-Chk1
(Ser345) (clone 133D3) rabbit MAb (Cell Signaling, Danvers, MA, USA) at the dilution of
1:100. Immunohistochemical staining was performed in an automated autostainer (BOND-III,
Leica, Milan, Italy) by a biotin-free polymeric horseradish peroxidase (HRP)-linker antibody
conjugate system (Leica, Milan, Italy). For each tumor, three different, 3 μm paraffin sections
were analyzed and examined by light microscopy. Immunoreaction of tumor cells was counted
in four high-power fields (400x magnification) per section. pWee1 and pChk1 were considered
positive when10% of the neoplastic cells showed a distinct nuclear immunoreactivity.
pWee1 and pChk1 were graded on a four-grade scale based on staining intensity (0: negative,
1+: weak, 2+: moderate, 3+: strong). Tumors were classified as negative (0 = pWee1neg and
pChk1neg) or positive (1–3 = pWee1pos and pChk1pos).The Allred scores were obtained as pre-
viously described [6], considering staining intensity and percentage of tumor-expressing cells,
and reported according to a scale of 0 to 8. Tumors were classified as low expressing if the
Allred score was 2 (pWee1allred low, pChk1allred low), or as high expressing if the Allred score
was> 2 (pWee1allred high, pChk1allred high). The multiplicative scores were obtained by multi-
plying staining intensity x the percentage of tumor-expressing cells, and were expressed on a
scale of 0 to 300. Tumors were classified as low expressing (pWee1multi low and pChk1multi low)
or high expressing (pWee1multi high and pChk1multi high) using the median score of all tumors as
a cut-off point. γ-H2AX expression was considered as the percentage of tumor-expressing cells
and analyzed both as continuous (γ-H2AXcont) and as categorical variable, whose modality was
defined using the median score of all tumors (γ-H2AX low and γ-H2AX high). Tumor samples
were evaluated independently by two investigators (SB and MC) who were blinded to treat-
ment outcomes, and discordant cases were reviewed (MM). This retrospective study was con-
ducted in accordance with the Declaration of Helsinki and was approved by the Ethic
Committee of “Regina Elena” National Cancer Institute of Rome, the coordinating centre.
Written informed consents were secured before chemotherapy.
Statistical analysis
Cancer- and patient-related features were descriptively characterized for all the patients
included in the present analysis. Medians and ranges were used to report on continuous vari-
ables, while categorical variables were expressed by frequencies and percentage values. In order
to assess the relationships between categorical variables the Pearson’s Chi-squared test of inde-
pendence (2-tailed) and the Fisher Exact test were employed. The use of univariate logistic
regression models helped identify variables potentially impacting treatment outcome. Multi-
variate logistic regression models were built by including variables testing significant at the uni-
variate assessment or identified based on the clinical plausibility of their role in influencing
pCR. To estimate the risk of an overfitted multivariate model and examine its stability, an
internal validation was carried out using a re-sampling procedure without replacement. To this
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end, one hundred datasets were generated by randomly removing approximately 20% of the
original sample. For each simulation, we repeated the multivariate logistic regression model
and the Cohen's Kappa coefficient, the Positive Predictive Value (PPV), the Negative Predictive
Value (NPV), Sensibility and Specificity were calculated. We considered statistically significant
p values less than 0.05. Statistical analyses were carried out using SPSS software (SPSS version
21, SPSS Inc., Chicago, IL, USA).
Results
Baseline characteristics of the 52 patients included in this study are summarized in Table 1.
Median time between diagnostic biopsy and radical surgery was 4.99 months [IQ Range: 4.01–
5.83]. All the pre-chemotherapy samples, consisting in diagnostic biopsies, were examined for
pWee1 and γ-H2AX, whereas pChk1 data were available for 37 samples. Median percentages
of nuclear-expressing cells for pWee1, pChk1 and γ-H2AX were 40% (min/max 10/80), 30%
(min/max 10/80) and 30% (min/max 0/80), respectively. Representative immunohistochemical
staining patterns are illustrated in Fig 1. As shown in Table 2, we found a statistically significant
association between elevated nuclear pWee1 expression and reduced pCR rate. The association
tested significant for all the scoring methods investigated (pWee1pos vs pWee1neg, p = 0.016;
pWee1allred high vs pWee1allred low, p = 0.016; pWee1multi high vs pWee1multi low, p = 0.034)
(Table 2). Likewise, elevated nuclear levels of γ-H2AX were associated with reduced pCR rate,
both when considered as categorical and continuous variable (p = 0.037 and p = 0.026 in
Table 2 and Fig 2, respectively). When considering the combination of the two markers, only 1
patient out of 16 with double positive tumors experienced a pCR, 9 out of 16 patients with dou-
ble negative tumors achieve a pCR, and an intermediate outcome was seen in patients whose
tumors expressed only one biomarker (p = 0.009) (Table 3). Six out of 8 deaths were observed
in double positive tumors (p = 0.013) (Table 3). In the univariate logistic regression model,
pWee1 and γ-H2AX were directly associated with pCR (pWee1pos vs pWee1neg: Odds Ratio
(OR) 5.31, 95% Confidence Interval (CI): 1.42–19.87, p = 0.013; γ-H2AXhigh vs γ-H2AXlow:
OR 4.20, 95%CI:1.13–15.59, p = 0.032, respectively) (Table 4); the multivariate model con-
firmed the predictive role of pWee1 and γ-H2AX (Table 4). The internal validation performed
through a re-sampling procedure confirmed the robustness of the multivariate model. Concor-
dance, Positive Predictive Value, Negative Predictive Value, Sensitivity and Specificity are
Table 1. Baseline characteristics and treatment outcome of cervical cancer patients treated with
neoadjuvant chemotherapy (N = 52).
Characteristics N (%)





Squamous cell carcinoma 43 (82.7)
Adenocarcinoma 9 (17.3)
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shown in Table 5. Finally, when investigating co-expression patterns, we did not observe any
association between pWee1 and γ-H2AX (data available upon request), whereas a statistically
significant association was reported between pWee1 and pChk1 (Fig 3).
Discussion
In the present study we retrospectively explored the predictive significance of pWee1 and γ-
H2AX expression, evaluated in diagnostic biopsies related 52 cervical cancer patients who
received neoadjuvant chemotherapy. We also investigated the association between pWee1 and
pChk1 in order to provide clues on whether Wee1 activation in cervical cancer is mediated by
Chk1. To our knowledge, this is the first study reporting on DNA damage and repair biomark-
ers in cervical cancer that exploited the concept of the defective nature of the G1/S-phase
checkpoint. Overall, we observed a statistically significant association between elevated
Fig 1. Representative examples of immunohistochemical expression of DNA damage and repair
biomarkers in cervical cancer patients. Three consecutive sections for each tumor are showed. (A-C) A
triple positive tumor with nuclear γ-H2AX(A), pWee1(B) and pChk1 (C) immunoreactivity.(D-F) A tumor that
did not express γ-H2AX (D), and that co-expressed pWee1(E) and pChk1 (F). (G-I) A tumor expressing
nuclear γ-H2AX (G) that lacked both pWee1(H) and pChk1 (I) expression.
doi:10.1371/journal.pone.0149872.g001
Table 2. Association between biomarkers of DNA damage and repair (pWee1 and γ-H2AX) and patho-
logical complete response in cervical cancer patients treated with neoadjuvant chemotherapy
(N = 52).
Pathological complete response
No Yes Fisher's Exact Test
Biomarker N (%) N (%) P-value
pWee1neg 13 (52.0) 12 (48.0) 0.016
pWee1pos 23 (85.2) 4 (14.8)
pWee1allred low 13 (52.0) 12 (48.0) 0.016
pWee1allred high 23 (85.2) 4 (14.8)
pWee1multi low 14 (53.8) 12 (46.2) 0.034
pWee1multi high 22 (84.6) 4 (15.4)
γ-H2AXcat low 15 (55.6) 12 (44.4) 0.037
γ-H2AXcat high 21 (84.0) 4 (16.0)
pWee1, phosphorylated Wee1-like protein kinase; γ-H2AX, phosphorylated H2A Histone Family Member X
doi:10.1371/journal.pone.0149872.t002
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expression of pWee1 and γ-H2AX and reduced rate of pCR. Thus, we provided first hints that
the elevated expression of DDR biomarkers in diagnostic samples might be associated with
suboptimal efficacy of chemotherapy, evaluated through pCR in surgically resected tumors.
We also observed a positive association between pWee1 and pChk1 expression that suggests
effective G2/M checkpoint activation. We are aware that our results are hypothesis-generating
Fig 2. Box plot of the distribution of γ-H2AX values by pathologic complete response. In the figure: the
upper horizontal line of the box is the 75th percentile; the lower horizontal line of the box is the 25th percentile;
the horizontal bar within box is the median value; the upper horizontal bar outside the box is the maximum
value; the lower horizontal bar outside the box is the minimum values.
doi:10.1371/journal.pone.0149872.g002
Table 3. Association between the co-expression of pWee1 and γ-H2AX and A) Pathological complete
response (N = 52), B) Death (N = 8).
Pathological complete
response
A) N = 52 No Yes Chi2
N (%) N (%) P-value
pWee1neg / γ-H2AXcat low 7 (43.8) 9 (56.3) 0.009
pWee1neg /γ-H2AXcat high or pWee1pos /γ-H2AXcat low 14 (70.0) 6 (30.0)
pWee1pos /γ-H2AXcat high 15 (93.8) 1 (6.2)
Death
B) N = 8 No Yes Chi2
N (%) N (%) P-value
pWee1neg /γ-H2AXcat low 15 (93.8) 1 (6.2) 0.013
pWee1neg /γ-H2AXcat high or pWee1pos /γ-H2AXcat low 19 (95.0) 1 (5.0)
pWee1pos /γ-H2AXcat high 10 (62.5) 6 (37.5)
pWee1, phosphorylated Wee1-like protein kinase; γ-H2AX, phosphorylated H2A Histone Family Member X
doi:10.1371/journal.pone.0149872.t003
DNA Damage Repair in Cervical Cancer Patients
PLOS ONE | DOI:10.1371/journal.pone.0149872 March 1, 2016 6 / 11
in nature given the retrospective design of the study. Nevertheless, beyond the straightforward
analytical approach, our study has some important strengths.
First, the neoadjuvant setting offers multiple advantages for the identification and develop-
ment of cancer biomarkers: i) the analysis of potential markers in a molecular background not
“polluted” by the exposure of previous anticancer treatments, ii) the identification of predictive
markers to select patients who will more likely benefit from chemotherapy, iii) the identifica-
tion of biomarkers that also hold prognostic significance, even though evidence on the associa-
tion between pCR and long-term survival outcomes in cervical cancer is not as robust as it is in
breast cancer [7, 8].
Second, thus far, in cervical cancer the search for predictive biomarkers linked to the
increased ability of cancer cells to protect their genome when challenged with chemotherapy or
radiotherapy has been exclusively focused on nucleotide excision repair (NER) proteins, and in
particular on the excision repair cross-complementation group1 (ERCC1) protein [9–13]. NER
is deputed to correct bulky helix-distorting lesions, such as those inflicted on the DNA by plati-
num-based therapy. However, within the context of the DDR, NER is one of the many distal
effectors assigned to maintain genome integrity. A number of molecular networks safeguard
the genome, albeit their engagement depends on the type of lesion. DNA repair pathways also
include base excision repair (BER), mismatch repair (MMR), direct repair, and the double-
strand break (DSB) recombinational repair. This latter encompasses the error-free homologous
recombination repair (HRR) and the error-prone non-homologous end-joining (NHEJ) [1].
Therefore, the level of biologic complexity of the DDR might be underestimated when exclu-
sively considering one, or few, components collocated in a specific repair network. Moreover,
concerns were raised on the reliability, and biological significance, of ERCC1 detection
Table 4. Uni andmultivariate logistic regression models of patient- and disease-related features and pathological complete response.
Univariate logistic regression model Multivariate logistic regression
model*
OR (95%CI) P-value OR (95%CI) P-value
Variables
Age >45.5 vs 45.5 0.70 (0.21–2.28) 0.549
Stage II-III vs I 1.36 (0.40–4.69) 0.623
Histology AC vs SCC Not applicable Not applicable
CT cycles 4 vs 3 2.46 (0.71–8.52) 0.156
γ-H2AX high vs low 4.20 (1.13–15.59) 0.032 7.14 (1.30–39.29) 0.024
pWee1 pos vs neg 5.31 (1.42–19.87) 0.013 8.92 (1.68–47.26) 0.010
* Adjusted for age, stage, number of chemotherapy cycles.
AC, Adenocarcinoma; SCC: Squamous cell carcinoma; CT, Chemotherapy.
doi:10.1371/journal.pone.0149872.t004
Table 5. Replication stability of the multivariate analysis after internal validation with a re-sampling procedure. One hundred less-powered simula-
tion datasets were generated, each approximately 80% of the original size.
Mean Median Minimum Maximum Standard Deviation
Cohen's kappa coefﬁcient 0.575 0.581 0.408 0.715 0.06
Positive predictive value (PPV) 0.741 0.742 0.600 0.888 0.05
Negative predictive value (NPV) 0.858 0.857 0.800 0.933 0.02
Sensitivity 0.660 0.667 0.440 0.800 0.06
Speciﬁcity 0.898 0.899 0.833 0.966 0.03
doi:10.1371/journal.pone.0149872.t005
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methods [14, 15]. Conversely, our study focused on master DDR components, whose activa-
tion is known to be particularly efficient in cervical cancer.
Next, we hypothesized that endogenous levels of DNA damage, mirrored by γ-H2AX,
should have been paralleled by increased expression of pWee1 and pChk1.Even though the
ATR-Chk1-Wee1 axis is primarily activated by stretched of single-stranded DNAs, these
abnormal structures may generate DSBs upon replication fork collapse [16]. Moreover, we rea-
soned that the activation of the G2/M checkpoint should be particularly proficient in the pres-
ence of high basal levels of endogenous DNA damages, representing an adaptive mechanism
through which cancer cells counteract oncogene-induced replication stress [16]. Indeed, it is
known that ATR and Chk1 suppress the apoptotic response following DNA replication stress
[17], and that tumors characterized by elevated levels of replicative stress, such as Myc-driven
cancers, are extremely vulnerable to the pharmacological targeting of G2/M checkpoint kinases
[18–23]. We did not observe any association between pWee1 and γ-H2AX, but rather these end-
points were independently associated with pCR.We can speculate that two independent repair
avenues, particularly efficient in cervical cancer, were captured in this study. A suitable candidate
is the Ataxia-telangiectasia mutated (ATM)-Checkpoint kinase 2 (Chk2) pathway, which is
mainly activated by DSBs [16]. An extensive cooperation exists between the ATM-Chk2 pathway
and ATR-Chk1-Wee1 signaling, and ATM also phosphorylates H2AX [16].
Fig 3. OncoPrints showing the association between pWee1 and pChk1 in 37 cervical cancer samples.
(A) Association according to staining intensity-based classification (positive vs negative). (B) Association
according to Allred score classification (high vs low). (C) Association according to a multiplicative score
classification (high vs low).
doi:10.1371/journal.pone.0149872.g003
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Another aspect emerging from this study relates to the association between pWee1 and
pChk1 expression. Wee1 is placed downstream Chk1 [3], and Wee1 phosphorylation at Ser642
increases its stability in the nucleus and promotes cell cycle arrest at the G2/M transition [24,
25]. However, to our knowledge formal proof that this regulatory mechanism, namely
Chk1-driven phosphorylation of Wee1 at Ser642, operates in mammalian cells is still lacking.
Current evidence mostly stems from studies using Xenopus extracts and Schizosaccharomyces
pombe as model systems [26, 27]. Even though our study was not designed to generate mecha-
nistic insights into the dynamics governing Wee1 activation, its results provide a suggestion for
future preclinical investigations.
A final point that deserves consideration refers to the protective role of G2/M checkpoint
activation in the context of cancer stem cells [28]. Activation of the axis has been associated
with therapeutic resistance in different cancer stem cell models, including brain, lung and
colon cancers [29–31]. Multiplying the efforts for establishing a collection of patient-derived
cervical cancer stem cells for comprehensive molecular characterization is a strategy that
should be pursued to further dissect the relationship existing between G2/M checkpoint activa-
tion and chemoresistant features. The relevance of this approach is even more evident when
considering the need for more accurate cellular and animal models in light of the number of
Chk1 and Wee1 inhibitors that entered clinical development [3, 32]. For instance, a phase I
trial with the first-in-class Wee1 inhibitor AZD1775 (MK1775) in association with cisplatin
and radiation therapy is ongoing (ClinicalTrials.gov Identifier: NCT01958658), and a phase I/
II trial in combination with topotecan/cisplatin results as completed (ClinicalTrials.gov Identi-
fier:NCT01076400). Moreover, a phase I-II trial of AZD1775 in combination with chemother-
apy has been initiated in patients with TP53-mutated epithelial ovarian, fallopian tube, or
primary peritoneal cancer [33].
Conclusions
To sum up, pWee1 andγ-H2AX expression in pre-chemotherapy samples showed ability to
foresee pCR in cervical cancer patients treated with neoadjuvant paclitaxel, ifosfamide and cis-
platin. Based on the extremely promising results herein presented prospective validation or,
alternatively, ancillary molecular analyses in the context of prospective trials is warranted to
better characterize the predictive ability of these biomarkers.
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